Related Experiment Video
Updated: Sep 20, 2025
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Genetic variants, gene expression, and soluble CD36 analysis in acute coronary syndrome: Differential protein
Brenda Parra-Reyna1,2, Jorge Ramón Padilla-Gutiérrez1, Maricela Aceves-Ramírez1,2
1Instituto de Investigación en Ciencias Biomédicas, Universidad de Guadalajara, Guadalajara, Mexico.
Insights
The CD36 gene variant rs1194182 may protect against acute coronary syndrome (ACS) but is linked to diabetes risk. Soluble CD36 levels correlate with ACS severity and diabetes.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
- Atherosclerosis Research
Background:
- Atherosclerosis is central to acute coronary syndrome (ACS) pathophysiology.
- CD36, a scavenger receptor, influences lipid metabolism.
- Non-coding CD36 variants may affect protein expression and function.
Purpose of the Study:
- Investigate gene and protein expression of CD36 variants in ACS patients.
- Analyze associations between CD36 variants (rs1194182, rs1049654, rs1334512, rs3211892) and ACS in a western Mexican population.
Main Methods:
- Recruited 310 ACS patients and 308 controls.
- Genotyping performed using TaqMan SNP assays.
- CD36 mRNA expression quantified by TaqMan gene expression assays.
- Soluble CD36 (sCD36) measured via enzyme-linked immunosorbent assay.
Main Results:
- The rs1194182 G>C variant showed a protective effect (1.7-fold lower ACS susceptibility), though masked by diabetes and dyslipidemia.
- Higher sCD36 concentration observed in ST-segment elevation myocardial infarction (STEMI) vs. unstable angina (UA) patients (p=0.038).
- Elevated sCD36 in diabetic vs. non-diabetic patients (p<0.001).
- Increased CD36 mRNA expression (1.91-fold) in ACS patients compared to controls (p=0.02).
Conclusions:
- rs1194182 appears associated with increased diabetes risk and dyslipidemia protection in ACS patients.
- sCD36 concentration correlates with ACS clinical spectrum and diabetes presence.
- STEMI patients exhibit significantly higher sCD36 levels than UA patients.
Background:
Atherosclerosis plays an important role in the pathophysiology of acute coronary syndrome (ACS). CD36 is a scavenger receptor involved in lipid metabolism. Some single-nucleotide variants in the non-coding region could indirectly alter the expression and the function of the protein.
Objective:
The aim of this study was to investigate the gene and protein expression associated with CD36 variants (rs1194182;C > G; rs1049654;C > A, rs1334512;G > T, and rs3211892;G > A) in ACS patients from the western Mexican population.
Methods:
We recruited 310 ACS patients and 308 subjects in the control group (CG). Genotyping was determined by TaqMan SNP genotyping assays. CD36 expression at the mRNA level was quantified by TaqMan gene expression assays. Soluble CD36 (sCD36) was measured by enzyme-linked immunosorbent assay.
Results:
We show that rs1194182G > C variant provides a protective effect with a 1.7-fold lower susceptibility to develop ACS (p = 0.03); however, this association was masked by diabetes and dyslipidemia. We observed a higher sCD36 concentration in patient with ST-segment elevation myocardial infarction (STEMI) compared with patients with unstable angina (UA) (p = 0.038). Likewise, in diabetic patients versus non-diabetic (p < 0.001). We observed in patients an increase in CD36 mRNA expression (1.91 times higher) than in the CG (p = 0.02).
Conclusion:
The rs1194182 seems to be associated with diabetes in a risky manner, in ACS patients and protective for dyslipidemia in both groups. The concentration of sCD36 seems to be associated with the clinical spectrum of the ACS patients and the presence of diabetes, since patients with STEMI present significantly elevated level compared with UA.
More Related Videos
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
04:41Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
Published on: July 3, 2018
Related Concept Videos
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Acute Coronary Syndrome I: Introduction
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...